The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
Official Title: A Study to Find the Highest Dose of Biological Study Drug (EMD 273066) That Can Be Given Safely to Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given a Low Dose of Cyclophosphamide
Study ID: NCT00132522
Brief Summary: This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small cell lung cancers. EMD 273066 is an experimental biological drug that may increase the immune response to certain cancers. Patients will be enrolled in groups of 3, with each successive group receiving a higher dose if the prior group adequately tolerates the study medication.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope, Durate, California, United States
Dartmouth Medical School, Pharmacology & Toxicology Dept. of Medicine, Lebanon, New Hampshire, United States
Fox Chase Cancer Oncology Department of Medical Oncology, Philadelphia, Pennsylvania, United States
University of Wisconsin Division of Gynecologic Oncology, Madison, Wisconsin, United States
Centre pluridisciplinaire d'Oncologie, Lausanne, Rue du Bugnon, Switzerland
Name: Joseph O'Connor, MD
Affiliation: University of Wisconsin, Madison
Role: PRINCIPAL_INVESTIGATOR